References
- Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333
- Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47–53
- The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clin Trials 1998;19:61–109
- Committee to review the NIH Women's Health Initiative, Thaul S, Hotra D, eds. An Assessment of the NIH Women's Health Initiative. Washington, DC: National Academy Press, 1993:53–58. http://www.nap.edu/openbook.php?record_id=2271&page=1
- Phillips LD, Langer, RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005;83:558–566
- Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613
- Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712
- Hsia J, Langer RD, Manson JE, et al Conjugated equine estrogens and coronary disease. Arch Intern Med 2006;166:357–365
- Stefanick ML, Anderson GL, Margolis KL, et al Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–1657
- Prentice RL, Manson JE, Langer RD, et al Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12–23
- Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35–44
- Manson JE, Hsia J, Johnson KC, et al Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–534
- von Fournier D, Weber E, Hoeffken W, et al Growth rate of 147 mammary carcinomas. Cancer 1980;45:2198–2207
- Chlebowski RT, Hendrix SL, Langer RD, et al Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–3253
- Harman SM, Brinton EA, Cedars M, et al KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
- Ridker PM, Cook NR, Lee IM, et al A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304
- American Heart Association. Facts about Women and Cardiovascular Diseases. http://www.americanheart.org/presenter.jhtml?identifier=2876
- International Menopause Society. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–194
- Pines A, Sturdee DW, Birkhäuser MH, et al Summary of the First IMS Global Summit on menopause-related issues, HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008;11:267–272
- North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–255